AOD-9604 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-05-31. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
The PAH world hypothesis is a speculative hypothesis that proposes that polycyclic aromatic hydrocarbons (PAHs), known to be abundant in the universe, including in comets, and assumed to be abundant in the primordial soup of the early Earth, played a major role in the origin of life by mediating the synthesis of RNA molecules, leading into the RNA world. However, as yet, the hypothesis is untested.
=== miRNA === MicroRNAs (miRNAs) have complementary sequences in the 3' UTR and 5' UTR of target mRNAs of protein-coding genes, and cause mRNA cleavage or repression of translational machinery. In diseased vascular vessels, miRNAs are dysregulated and highly expressed. miR-33 is found in cardiovascular diseases. It is involved in atherosclerotic initiation and progression including lipid metabolism, insulin signaling and glucose homeostatis, cell type progression and proliferation, and myeloid cell differentiation. They found in rodents that the inhibition of miR-33 raises HDL-C levels, and miR-33 expression is down-regulated in humans with atherosclerotic plaques. miR-33a and miR-33b are located on intron 16 of human sterol regulatory element-binding protein 2 (SREBP2) gene on chromosome 22 and intron 17 of SREBP1 gene on chromosome 17. miR-33a/b regulates cholesterol/lipid homeostasis by binding in the 3'UTRs of genes involved in cholesterol transport, such as ATP binding cassette (ABC) transporters, and enhances or represses their expression. Studies have shown that ABCA1 mediates cholesterol transport from peripheral tissues to Apolipoprotein-1. It is also important in the reverse cholesterol transport pathway, where cholesterol is delivered from peripheral tissue to the liver, where it can be excreted into bile or converted to bile acids before excretion. Therefore, ABCA1 prevents cholesterol accumulation in macrophages. By enhancing miR-33 function, ABCA1 levels decrease, leading to decreased cellular cholesterol efflux to apoA-1.
== Application == Knowing the direction of Langer's lines within a specific area of the skin is important for surgical operations, particularly cosmetic surgery. If a surgeon has a choice about where and in what direction to place an incision, they may choose to cut in the direction of Langer's lines. Incisions made parallel to Langer's lines may heal better and produce less scarring than those that cut across. Conversely, incisions perpendicular to Langer's lines have a tendency to pucker and remain obvious, although sometimes this is unavoidable. The orientation of stab wounds relative to Langer's lines can have a considerable impact upon the presentation of the wound. Langer's lines include breast static tension lines, which mark a guide for breast surgery incisions. Keloids are more common when incision is given across Langer's lines. Sometimes the exact direction of the collagen fibers are unknown, because in some regions of the body there are differences between different individuals.
Sources: en.wikipedia.org
=== Future technology and research === Gene therapy is being explored as a treatment for missense mutations. This involves inserting the correct sequence of DNA into an incorrect gene. Artificial Intelligence programs, such as AlphaFold, are also being developed to predict the effect of missense mutations. Identifying potential deleterious mutations can assist with disease diagnosis and treatment.
== Company history == Digico was founded in 1965 by Keith Trickett and Avo Hiiemae, two ex-ICL electronics engineers. Former MP Eric Lubbock was chairman from 1969 to 1983. The company was based in Letchworth initially, moving to a new factory in Stevenage in 1973 and employing about 90 staff. Digico's first product was a laboratory data-logging and spectrum analyser hardware system named DIGIAC. A prototype had been developed before Digico was formed, by the founders in a garage, so became an immediate source of income. Digico soon developed a 16-bit minicomputer series, the Micro 16, for which it was best known for. In 1974 Digico had a turnover of over £1 million (equivalent to £9 million in 2025) and in 1977 well over £1 million. Spanverne Investments raised a large private capital investment into Digico in 1981, while the new Prince product was being developed. In October 1982, Digico announced it would close its Stevenage factory with the loss of 130 jobs within six months. This was part of a rationalisation plan to concentrate manufacturing at its large Leeds site. It would retain its Letchworth site primarily as a south England office. On 1 February 1984, the Financial Times reported that after a weekend of failed negotiation between British computer company Optim and Midland Bank, Digico went into receivership on 30 January 1984. Digico owed more that £400,000 to Midland Bank and over £1 million to other creditors.
There was worse to follow, with various Essendon players publicly blaming each other for a poor performance against Richmond, and then, with dissension still rife in the ranks, the side plummeted to an unexpected and humiliating 28-point loss to VFA premiers Footscray in a special charity match played a week later in front of 46,100 people, in aid of Dame Nellie Melba's Limbless Soldiers' Appeal Fund, purportedly (but not officially) for the championship of Victoria. The club's fortunes dipped alarmingly—and persistently. Indeed, after finishing third in the 1926 season, it was to be 14 years later—in 1940—before Essendon would even contest another finals series.
=== Post-operative management === A 2019 Cochrane systematic review aimed to determine whether rigid dressings were more effective than soft dressings in helping wounds heal following transtibial (below the knee) amputations. Due to the limited and very low certainty of evidence available, the authors concluded that it was uncertain what the benefits and harms were for each dressing type. They recommended that clinicians consider the pros and cons of each dressing type on a case-by-case basis: rigid dressings may potentially benefit patients who have a high risk of falls; soft dressings may potentially benefit patients who have poor skin integrity. A 2017 review found that the use of rigid removable dressings (RRD's) in trans-tibial amputations, rather than soft bandaging, improved healing time, reduced edema, prevented knee flexion contractures and reduced complications, including further amputation, from external trauma such as falls onto the stump. Post-operative management, in addition to wound healing, considers maintenance of limb strength, joint range, edema management, preservation of the intact limb (if applicable) and stump desensitization.
Sources: en.wikipedia.org
indicate that the four-fold degeneracy (two valley and two spin degrees of freedom) of the Landau energy levels is partially or completely lifted. One hypothesis proposes that magnetic catalysis of symmetry breaking is responsible for this degeneracy lift.
FGF-1 stimulates the proliferation and differentiation of all cell types necessary for building an arterial vessel, including endothelial cells and smooth muscle cells; this fact distinguishes FGF-1 from other pro-angiogenic growth factors, such as vascular endothelial growth factor (VEGF), which primarily drives the formation of new capillaries. Besides FGF-1, one of the most important functions of fibroblast growth factor-2 (FGF-2 or bFGF) is the promotion of endothelial cell proliferation and the physical organization of endothelial cells into tube-like structures, thus promoting angiogenesis. FGF-2 is a more potent angiogenic factor than VEGF or PDGF (platelet-derived growth factor); however, it is less potent than FGF-1. As well as stimulating blood vessel growth, aFGF (FGF-1) and bFGF (FGF-2) are important players in wound healing. They stimulate the proliferation of fibroblasts and endothelial cells that give rise to angiogenesis and developing granulation tissue; both increase blood supply and fill up a wound space/cavity early in the wound-healing process.
=== Methylene blue value of fine aggregate === The methylene blue value is defined as the number of milliliters of standard methylene blue solution decolorized 0.1 g of activated carbon (dry basis). Methylene blue value reflects the amount of clay minerals in aggregate samples. In materials science, methylene blue solution is successively added to fine aggregate which is being agitated in water. The presence of free dye solution can be checked with a stain test on a filter paper.
Cross-flow membrane filtration technology has been used widely in industry around the globe. Filtration membranes can be polymeric or ceramic, depending upon the application. The principles of cross-flow filtration are used in reverse osmosis, nanofiltration, ultrafiltration and microfiltration. When purifying water, it can be very cost-effective in comparison to the traditional evaporation methods. In protein purification, the term tangential flow filtration (TFF) is used to describe cross-flow filtration with membranes. The process can be used at different stages during purification, depending on the type of membrane selected. In the photograph of an industrial filtration unit (right), it is possible to see that the recycle pipework is considerably larger than either the feed pipework (vertical pipe on the right hand side) or the permeate pipework (small manifolds near to the rows of white clamps). These pipe sizes are directly related to the proportion of liquid that flows through the unit. A dedicated pump is used to recycle the feed several times around the unit before the solids-rich retentate is transferred to the next part of the process.
In the field of engineering, the hydrophobicity (or dewetting ability) of a flat surface (e.g., a counter top in kitchen or a cooking pan) can be measured by the contact angle of water droplet. A University of Nebraska–Lincoln team devised a computational approach that can relate the molecular hydrophobicity scale of amino-acid chains to the contact angle of water nanodroplet. The team constructed planar networks composed of unified amino-acid side chains with native structure of the beta-sheet protein. Using molecular dynamics simulation, the team is able to measure the contact angle of water nanodroplet on the planar networks (caHydrophobicity). On the other hand, previous studies show that the minimum of excess chemical potential of a hard-sphere solute with respect to that in the bulk exhibits a linear dependence on cosine value of contact angle. Based on the computed excess chemical potentials of the purely repulsive methane-sized Weeks–Chandler–Andersen solute with respect to that in the bulk, the extrapolated values of cosine value of contact angle are calculated(ccHydrophobicity), which can be used to quantify the hydrophobicity of amino acid side chains with complete wetting behaviors.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.